Hosted on MSN1mon
Mersana falls after early-stage trial data for lead cancer therapy
Cancer drug developer Mersana Therapeutics (NASDAQ:MRSN) hit a 52-week low on Friday after sharing early clinical results from a Phase 1 trial for its lead candidate emiltatug ledadotin (Emi-Le ...
ETF Daily News1mon
Mersana Therapeutics’ (MRSN) Outperform Rating Reiterated at Wedbush
Wedbush reiterated their outperform rating on shares of Mersana Therapeutics (NASDAQ:MRSN – Free Report) in a research report released on Friday morning,RTT News reports. They currently have a $ ...
ETF Daily News1mon
Mersana Therapeutics Announces Positive Initial Clinical Data and FDA Fast Track Designation for Emiltatug Ledadotin (XMT-1660)
Mersana Therapeutics, Inc. recently disclosed encouraging updates in a Form 8-K report filed with the Securities and Exchange Commission. The company unveiled positive initial clinical data from ...
AOL1mon
Why Is Cancer-Focused Mersana Therapeutics Stock Trading Lower On Friday?
On Friday, Mersana Therapeutics Inc. (NASDAQ:MRSN) released initial data from the Phase 1 dose escalation and backfill cohorts for emiltatug ledadotin. Emi-Le was generally well tolerated ...